


Curriculum Vitae

Name	Ishwaria Subbiah, MD	
Current Position & Affiliation	Assistant Professor The University of Texas MD Anderson Cancer Center	
Country	United States	

Educational Background

Johns Hopkins University, Baltimore, MD, BS, 2004, Molecular and Cellular Biology
 Johns Hopkins University, Baltimore, MD, MS, 2005, Biotechnology
 St. George's University, St. George, GND, MD, 2008, Doctor of Medicine
 Clinical Residency, Internal Medicine, University of Texas Health Science Center at Houston, TX, 2009-2011
 Clinical Fellowship, Investigational Cancer Therapeutics (A Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX, 2011-2012
 Clinical Fellowship, Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 2012-2015
 Clinical Fellowship, Hospice and Palliative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 2015-2016

Professional Experience

Assistant Professor, Department of Palliative Care and Rehabilitation Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2016-present
 Andrew Sabin Family Foundation Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2019-present
 Chair, Patient Survey Informatics Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2018-present

Professional Organizations

American Association for Cancer Research (AACR)
 Member, 1/2011-present
 American Society of Clinical Oncology (ASCO)
 Member, 1/2011-present
 Member, ASCO Audit Committee, 5/2017
 Member, Social Media Working Group, 8/2019-present
 Chair-Elect, Social Media Working Group, 8/2020-present

International Society of Geriatric Oncology (SIOG)

Member, 5/2014-present

Southwest Oncology Group (SWOG), Portland, OR

Member, 3/2017-present

Member, Palliative and End-of-Life Care Working Group, 8/2017-7/2018

Member, Palliative Care and End-of-Life Care Committee (PCEOLC), 7/2018-present

American Academy of Hospice and Palliative Medicine (AAHPM), Chicago, IL

Member, 4/2017-present

Academic Consortium for Integrative Medicine & Health

Member, 6/2017-present

Cancer and Aging Research Group (CARG)

Member, 6/2017-present

Co-Chair, Communications Core, 1/2019-present

Multinational Association of Supportive Care in Cancer (MASCC)

Member, 10/2017-present

Member, Geriatric Oncology Subgroup, 6/2018-present

Member, Neurological Complications Subgroup, 6/2018-present

Main Scientific Publications

1. Subbiah IM, Lenihan DJ, Tsimberidou AM. Cardiovascular toxicity profiles of vascular-disrupting agents. *Oncologist* 16(8):1120-30, 2011. e-Pub 7/2011. PMID: PMC3228163.
2. Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. *Hepatology* 59(116):960-4, 6/2012. PMID: 22580643.
3. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheeler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. *Oncotarget* 4(1):156-65, 1/2013. PMID: PMC3702215.
4. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheeler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. *Cancer Chemother Pharmacol* 71(2):389-97, 2/2013. e-Pub 11/2012. PMID: 23143207.
5. Subbiah V, Subbiah IM. Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. *Ann Hematol* 92(8):1149, 8/2013. e-Pub 1/2013. PMID: 23322213.
6. Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. *Oncology* 85(4):197-203, 2013. e-Pub 9/2013. PMID: PMC3913463.
7. Subbiah IM, Gonzalez-Angulo AM. Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future. *Curr Treat Options Oncol* 15(1):41-54, 3/2014. PMID: PMC3933950.
8. Subbiah IM, Blackmon SH, Correa AM, Kee B, Vaporciyan AA, Swisher SG, Eng C. Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. *Oncotarget* 5(16):6584-93, 8/2014. PMID: PMC4196147.
9. Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, Mayfield J, Miller VA, Stephens PJ, Ross JS, Ali SM. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid

- features harboring DCTN1-ALK fusion. *J Hematol Oncol* 8:66, 6/2015. e-Pub 6/2015. PMID: PMC4467062.
10. Subbiah V, Berry J, Roxas M, Guha-Thakurta N, Subbiah IM, Ali SM, McMahon C, Miller V, Cascone T, Pai S, Tang Z, Heymach JV. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. *Lung Cancer* 89(1):76-9, 7/2015. e-Pub 4/2015. PMID: PMC4998046.
 11. Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. *J Clin Oncol* 33(20):2239-45, 7/2015. e-Pub 5/2015. PMID: PMC5098846.
 12. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. *Oncotarget* 6(29):28453-62, 9/2015. PMID: PMC4695071.
 13. Subbiah IM, Subbiah V. Exceptional responders: in search of the science behind the miracle cancer cures. *Future Oncol* 11(1):1-4, 2015. PMID: 25572778.
 14. Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. *Oncology* 90(6):339-46, 2016. e-Pub 5/2016. PMID: PMC4909575.
 15. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients 65 years old with advanced cancer treated on phase I trials at MD Anderson Cancer Center. *Int J Cancer* 140(1):208-215, 1/2017. e-Pub 10/2016. PMID: 27599876.
 16. Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong DS. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. *Oncoscience* 4(5-6):47-56, 5/2017. e-Pub 6/2017. PMID: PMC5538848.
 17. Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. *Br J Cancer* 118(6):763-769, 3/2018. e-Pub 2/2018. PMID: PMC5886120.
 18. Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. *Oncotarget* 9(48):28842-28848, 6/2018. e-Pub 6/2018. PMID: PMC6034739.
 19. Menta AK, Subbiah IM, Subbiah V. Bringing wearable devices into oncology practice: fitting smart technology in the clinic. *Discov Med* 26(145):261-270, 12/2018. PMID: 30695675.
 20. Subbiah IM, Hamilton E, Knoll M, Shanahan K, Meisel J. A Big World Made Small: Using Social Media to Optimize Patient Care. *Am Soc Clin Oncol Educ Book* 39(39):e212-e218, 1/2019. e-Pub 5/2019. PMID: 31099651.
 21. Adashek JJ, Subbiah IM, Subbiah V. Artificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and Coexist. *Oncologist* 24(10):1291-1293, 10/2019. e-Pub 7/2019. PMID: PMC6795157.
 22. Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ, Staff NP, Kamath J, Oh J, Shinde S, Pon D, Dixit N, D'Olimpio J, Dumitrescu C, Gobbo M, Kober K, Mayo S, Pang L, Subbiah I, Beutler AS, Peters KB, Loprinzi C, Lustberg MB. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. *Support Care Cancer* 27(10):3729-3737, 10/2019. e-Pub 7/2019. PMID: PMC6728179.
 23. Sheikh AR, Hsu T, Subbiah IM, Arora SP. Perspectives on Geriatric Oncology Research presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. *J Geriatr Oncol* 10(6):998-1002, 11/2019. e-Pub 7/2019. PMID: 31326394.
 24. Subbiah IM, Lundebjerg N, Appleby J, Wallach G, Beilenson J, Dale W. Development of a strategic plan for the dissemination and communication of aging research through the Cancer and Aging Research Group (CARG) infrastructure grant. *J Geriatr Oncol* 11(2):359-360, 3/2020. e-Pub 7/2019. PMID: PMC6981062.
 25. Adashek JJ, Subbiah IM, Matos I, Garralda E, Menta AK, Ganeshan DM, Subbiah V. Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact? *Trends Cancer* 6(3):181-191, 3/2020. e-Pub 2/2020. PMID: 32101722.
 26. Magnuson A, Li D, Hsu T, Loh KP, MacKenzie A, Presley CJ, Krok-Schoen JL, Subbiah IM, Williams GR, Wong M, Soto-Perez-de-Celis E, Sedrak MS, Junior Cancer and Aging Research Group. Mentoring

- pearls of wisdom: Lessons learned by mentees of Arti Hurria, MD. *J Geriatr Oncol* 11(2):335-337, 3/2020. e-Pub 5/2019. PMID: 31160209.
27. Ludmir EB, Subbiah IM, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Mandel JJ, Fang P, Smith BD, Smith GL, Pinnix CC, Sedrak MS, Kimmick GG, Stinchcombe TE, Jagsi R, Thomas CR, Fuller CD, VanderWalde NA. Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. *J Geriatr Oncol* 11(3):451-454, 4/2020. e-Pub 11/2019. PMCID: PMC7370694.
 28. Battisti NML, Lok WCW, Subbiah I, Okonji D, Desideri I, Soto-Perez-De-Celis E. Perspectives on geriatric oncology research presented at the 2019 San Antonio Breast Cancer Symposium. *J Geriatr Oncol* 11(4):740-744, 5/2020. e-Pub 2/2020. PMID: 32044301.
 29. Giri S, Chakiba C, Shih YY, Chan WL, Krok-Schoen JL, Presley CJ, Williams GR, Subbiah IM. Integration of geriatric assessment into routine oncologic care and advances in geriatric oncology: A young International Society of Geriatric Oncology Report of the 2020 American Society of Clinical Oncology (ASCO) annual meeting. *J Geriatr Oncol*. e-Pub 7/2020. PMID: 32732011.
 30. Adashek JJ, Subbiah IM. Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers. *ESMO Open* 5(5):e000862, 9/2020. PMCID: PMC7509963.
 31. Kouzy R, Abi Jaoude J, Minsky BD, Das P, Koong AC, Subbiah IM, Ludmir EB, Taniguchi CM. Gastrointestinal malignancies and supportive care trials: a snapshot of the last two decades. *BMJ Support Palliat Care*. e-Pub 9/2020. PMID: 32943466.
 32. Pasalic D, McGinnis GJ, Fuller CD, Grossberg AJ, Verma V, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Diefenhardt M, Das P, Subbiah V, Subbiah IM, Jagsi R, Garden AS, Fokas E, Rödel C, Thomas CR, Minsky BD, Ludmir EB. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. *Eur J Cancer* 136:176-185, 9/2020. e-Pub 7/2020. PMID: 32702645.
 33. Lin TA, Fuller CD, Verma V, Mainwaring W, Espinoza AF, Miller AB, Jethanandani A, Pasalic D, Das P, Minsky BD, Thomas CR, Fogelman DR, Subbiah V, Subbiah IM, Ludmir EB. Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. *Cancers (Basel)* 12(9), 9/2020. e-Pub 9/2020. PMID: 32947844.
 34. Dhawan N, Prommer E, Sinclair CT, Subbiah IM. Development of a Patient-Centered Framework for Oncology Clinicians to Address Uncertainty in Cancer Care During the COVID-19 Pandemic. *Curr Treat Options Oncol* 21(12):99, 10/2020. e-Pub 10/2020. PMCID: PMC7594962.
 35. Abi Jaoude J, Kouzy R, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Pasalic D, Verma V, VanderWalde NA, Smith BD, Smith GL, Fuller CD, Das P, Minsky BD, Rödel C, Fokas E, Jagsi R, Thomas CR, Subbiah IM, Taniguchi CM, Ludmir EB. Performance Status Restriction in Phase III Cancer Clinical Trials. *J Natl Compr Canc Netw* 18(10):1322-1326, 10/2020. e-Pub 10/2020. PMID: 33022640.
 36. Desai A, Subbiah IM, Subbiah V. Advances in cancer research dissemination through the pandemic and beyond. *Annals of Oncology*. e-Pub 2/2021. PMID: 33636283.
 37. Reddy A, Arthur J, Dalal S, Hui D, Subbiah I, Wu J, Anderson AE, Castro D, Joy M, Nweke C, Gogineni M, Maddi R, Rozman de Moraes A, Shelal Z, Bruera E. Rapid Transition to Virtual Care during the COVID-19 Epidemic: Experience of a Supportive Care Clinic at a Tertiary Care Cancer Center. *J Palliat Med*. e-Pub 2/2021. PMID: 33535019.
 38. Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, Sherman SI, Meric-Bernstam F, Ryan AJ, Heymach JV, Subbiah V. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. *ESMO Open* 6(2):100079. e-Pub 3/2021. PMCID: PMC7973128.
 39. Christopherson KM, Das P, Berling C, Lindsay WD, Ahern C, Smith BD, Subbiah I, Koay EJ, Koong AC, Holliday EB, Ludmir EB, Minsky B, Taniguchi C, Smith GL. A Machine Learning Model Approach to Risk-Stratify Gastrointestinal (GI) Cancer Patients for Hospitalization and Mortality Outcomes. *Int J Radiat Oncol Biol Phys*. e-Pub 4/2021. PMID: 33933480.
 40. Premnath N, Sumarsono A, Sedhom R, Johnson DH, Subbiah IM, Dy SM, Gupta A. Use of Peripheral μ -Opioid Receptor Antagonists for Treating Opioid-Induced Constipation among US Medicare Beneficiaries from 2014 to 2018. *J Palliat Med*. e-Pub 4/2021. PMID: 33872062.
 41. Subbiah IM*, Yeh JC*, Dhawan N, Thompson BW, Hildner Z, Jawed A, Prommer E, Sinclair CT. (*Coequal first authors). Visitation Policies at NCI-Designated Comprehensive Cancer Centers during the COVID-19 Pandemic. *Support Care Cancer*. e-Pub 4/2021. PMCID: PMC8016614.

42. Nipp RD, Subbiah IM, Loscalzo M. Convergence of Geriatrics and Palliative Care to Deliver Personalized Supportive Care for Older Adults With Cancer. *J Clin Oncol*:JCO2100158. e-Pub 5/2021. PMID: 34043435.
43. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol* 18(5):313-319, 5/2021. e-Pub 3/2021. PMID: PMC7957448.
44. Subbiah IM*, Dhawan N*, Yeh JC, Thompson B, Hildner Z, Jawed A, Prommer E, Sinclair C. *Co-equal first authors. Healthcare Disparities and the COVID-19 Pandemic: Analysis of Primary Language and Translations of Visitor Policies at NCI-designated Comprehensive Cancer Centers. *J Pain Symptom Manage* 61(5):e13-e16, 5/2021. e-Pub 2/2021. PMID: PMC7955247.
45. Mayo SJ, Lustberg M, M Dhillon H, Nakamura ZM, Allen DH, Von Ah D, C Janelins M, Chan A, Olson K, Tan CJ, Toh YL, Oh J, Grech L, Cheung YT, Subbiah IM, Petranovic D, D'Olimpio J, Gobbo M, Koeppen S, Loprinzi CL, Pang L, Shinde S, Ntukidem O, Peters KB. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. *Support Care Cancer* 29(6):2821-2840, 6/2021. e-Pub 11/2020. PMID: 33231809.
46. Ganeshan D, Kambadakone A, Nikolaidis P, Subbiah V, Subbiah IM, Devine C. Current update on gallbladder carcinoma. *Abdom Radiol (NY)* 46(6):2474-2489, 6/2021. e-Pub 1/2021. PMID: 33386907.
47. Subbiah IM, Charone MM, Roszik J, Haider A, Vidal M, Wong A, Bruera E. Association of Edmonton Symptom Assessment System Global Distress Score with Overall Survival in Patients with Advanced Cancer. *JAMA Network Open*, 7/2021. e-Pub .
48. Hui D, Darke AK, Guthrie KA, Subbiah IM, Unger JM, Hershman DL, Krouse RS, Bakitas M, O'Rourke MA. Association between Health-Related Quality of Life and Progression Free Survival in Patients with Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. *JCO Oncology Practice*. In Press.
49. Wang XS, Srour S, Whisenant M, Subbiah I, Chen TH, Ponce D, Garcia-Gonzalez A, Kamal M, Mendoza T, Cleeland C, Kebriaei P, Neelapu S, Rezvani K, Ahmed S, Shpall E. Patient-reported symptom and functioning status during the first 12 months after CAR T-cell therapy for hematological malignancies. *Transplantation and Cellular Therapy*. In Press.